More han 60% of the country's population now has access to Pacific Edge's diagnostic bladder cancer tests, with the latest signing of another district health board.
Capital & Coast's recent signing follows that of Counties Manukau and Tairawhiti boards during the past quarter, joining healthcare providers in Canterbury, Bay Of Plenty/Lakes, MidCentral and Waitemata in their use of Cxbladder.
While Dunedin-headquartered Pacific Edge's target market remains the tens of millions of potential customers in the United States, the non-invasive Cxbladder urine test is gaining traction in New Zealand.
The company has certified laboratories in Pennsylvania, in the northeast US, and Dunedin.
Pacific Edge vice-president commercial and franchise Brent Powell said there were clear benefits for patients, in the detection and management of bladder cancer, including not requiring an invasive cystoscopy procedure.
Pacific Edge shares were trading at 40c yesterday.
In May Pacific Edge reported a loss of $19.7million for its year's trading to March, which was a 13% improvement on last year's record $22.6million loss.
